Wall Street Zen Downgrades Thermo Fisher Scientific (NYSE:TMO) to Hold

Thermo Fisher Scientific (NYSE:TMO) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.

Several other research analysts have also recently issued reports on the company. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Evercore ISI lifted their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $589.10.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $524.80 on Friday. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $610.97. The business’s fifty day moving average is $489.83 and its 200 day moving average is $447.66. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $198.17 billion, a P/E ratio of 30.35, a P/E/G ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last 90 days. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Institutional investors have recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Lafayette Investments Inc. boosted its holdings in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after buying an additional 22 shares during the period. Challenger Wealth Management boosted its holdings in shares of Thermo Fisher Scientific by 3.1% in the 2nd quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after buying an additional 22 shares during the period. Security National Bank of Sioux City Iowa IA boosted its holdings in shares of Thermo Fisher Scientific by 0.3% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock valued at $2,655,000 after buying an additional 22 shares during the period. Finally, Diversified Enterprises LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the 3rd quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock valued at $684,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.